4basebio wins deal to supply clinical-grade DNA for pharma client’s Phase I cell therapy trial

Bitget2026/09/28 06:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

4basebio will supply clinical-grade opDNA DNA starting material for a multinational pharmaceutical company’s Phase I cell therapy trial.
TriLink BioTechnologies was selected as CDMO to manufacture the mRNA drug substance using its CleanCap co-transcriptional capping technology.
Deal extends an existing Tier 1 pharma customer relationship into cell therapy programs, linking opDNA supply with TriLink’s GMP mRNA manufacturing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4BASEBIO plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609280200PR_NEWS_PRUKDSCX_0002) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

4basebio wins deal to supply clinical-grade DNA for pharma client’s Phase I cell therapy trial

You may also like

Crypto prices